01—Abstract
Summary
Summary of the 10-K filed April 1, 2002. Cited figures are marked; the original filing is the authoritative source.
UnitedHealth Group's 2001 Form 10-K, filed April 1, 2002, reports a strong year driven by revenue growth and margin expansion.
Consolidated revenues reached a record $23.5 billiona (up 11%), earnings from operations rose 31% to $1.6 billion, and diluted EPS was $2.79 (up 33%). The consolidated operating margin improved to 6.7% from 5.7%, mainly from productivity gains and a mix shift toward higher-margin fee-based products. Return on shareholders' equity rose to 24.5% from 19.0%.
Growth was broad across segments. Health Care Services (UnitedHealthcare and Ovations) generated $20.5 billionb in revenue, with commercial premium yield increases above 13%, while Uniprise, Specialized Care Services and Ingenix all grew revenue and operating earnings at double-digit rates. Medicare+Choice remains a managed risk: the company withdrew from counties affecting 56,000 members in 2001 and 57,000 more in 2002, and the AARP contract (about $3.5 billion in annual premiums) is a major concentration.
Cash flow from operations exceeded $1.8 billionc, and the company repurchased 19.6 million shares for about $1.1 billion. The balance sheet grew more leveraged. Debt rose to $1.6 billion, and the debt-to-total-capital ratio increased to 28.9% from 24.7%, close to management's 30% ceiling.
The filing also flags an ongoing set of class action and multi-district litigation (MDL No. 1334) alleging ERISA and RICO violations, along with regulatory exposure (HIPAA compliance deadlines in 2002-2003). Management states that none of these matters is expected to have a material adverse effect, though the risks are disclosed in detail.
02—Key points
Key Highlights
- Record 2001 revenues of $23.5 billion, up 11% year over year, with premium revenues of $20.7 billion
- Earnings from operations of $1.57 billion, up 31%; net earnings of $913 million, up 30%
- Diluted EPS of $2.79, up 33% from $2.19 in 2000
- Consolidated operating margin widened to 6.7% from 5.7%, aided by productivity gains and a shift toward fee-based products
- Return on shareholders' equity of 24.5%, up from 19.0%; operating cash flow of $1.84 billion, up 21%
- Debt-to-total-capital ratio rose to 28.9% from 24.7%, approaching the self-imposed 30% ceiling; total debt of $1.58 billion
- Repurchased 19.6 million shares for about $1.1 billion; board authorized an additional 30 million shares in February 2002
03—Questions
Frequently Asked Questions
What drove the increase in UnitedHealth's 2001 profitability?
Profitability improved on several fronts. Average net premium yield increases above 13% on UnitedHealthcare's renewing commercial business outpaced medical cost growth, and the operating cost ratio fell to 16.0% on a comparable revenue mix. Growth in higher-margin fee-based products also contributed. Management attributes much of the operating improvement to process, technology and claims productivity initiatives.
How exposed is UnitedHealth to the AARP contract and Medicare business?
The AARP contract provides about $3.5 billion in annual premium revenue from roughly 3.5 million members, a significant concentration. Medicare+Choice operations are being scaled back in unprofitable counties, with withdrawals affecting 56,000 members in 2001 and 57,000 in 2002, and Medicare enrollment fell about 15%. Management says it will keep offering products only in economically viable markets, and it cannot guarantee that Medicare operations will be profitable.
What litigation and regulatory risks does the company face?
UnitedHealth is a defendant in consolidated class actions (MDL No. 1334) alleging ERISA and RICO violations, along with separate suits such as the AMA case over non-network reimbursement rates. Several of these matters are in the motion-to-dismiss and class-certification stages. The company also faces ongoing government audits and investigations and must meet HIPAA privacy and transaction standards by 2002-2003. Management does not believe these matters will have a material adverse effect, but outcomes are uncertain.
Is the company's debt load a concern for investors?
Total debt and commercial paper rose to $1.58 billion from $1.21 billion, and the debt-to-capital ratio reached 28.9%, against a stated target range of 25-30%. The company is in compliance with its debt covenants, has $900 million of credit facilities and $450 million of shelf capacity, and holds senior debt ratings of A/A3. Management notes that a significant ratings downgrade could raise borrowing costs.
04—Continue